123
Participants
Start Date
October 14, 2021
Primary Completion Date
August 10, 2023
Study Completion Date
July 31, 2026
Vimseltinib
Administered orally
Placebo
Administered orally
Memorial Sloan-Kettering Cancer Center, New York
Duke Sarcoma Research, Durham
Ohio State University, Columbus
Mayo Clinic Rochester, Rochester
University of Kansas, Kansas City
University of Texas MD Anderson Cancer Center, Houston
University of Colorado, Aurora
City of Hope, Duarte
UC Davis Comprehensive Cancer Center, Sacramento
Seattle Cancer Care Alliance, Seattle
Dana Farber Cancer Institute, Boston
Chris O'Brien Lifehouse, Camperdown
McGill University, Montreal
Princess Margaret Hospital, Toronto
Institut Bergonié, Bordeaux
Centre Léon Bérard, Lyon
Institut Gustave Roussy, Villejuif
Helios Klinikum Berlin-Buch, Berlin
University Hospital Essen (Universitätsklinikum Essen), Essen
Prince of Wales Hospital, Hong Kong
Istituto Ortopedico Rizzoli, Bologna
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale", Naples
Istituto Oncologico Veneto, Padua
Istituto Nazionale Tumori Regina Elena, Rome
Leiden University Medical Center, Leiden
Oslo University Hospital, Oslo
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warsaw
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall d'Hebron, Barcelona
Fundacion Jimenez Diaz, Madrid
Hospital Clinico San Carlos, Madrid
Universitäts-Kinderspital beider Basel (UKBB), Basel
Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, London
University College London Hospitals, London
Lead Sponsor
Deciphera Pharmaceuticals, LLC
INDUSTRY